普罗布考联合阿托伐他汀对急性脑梗死患者颈动脉粥样硬化斑块的影响  

Effect of probucol combined with atorvastatin on carotid atherosclerosis plaque in patients with acute cerebral infarction

作　　者：马璟曦[1] 蔡敏[1] 

机构地区：[1]重庆市中山医院神经内科,400013

出　　处：《重庆医学》2013年第16期1835-1836,1840,共3页Chongqing medicine

摘　　要：目的观察普罗布考联合阿托伐他汀对急性脑梗死患者血脂及颈动脉粥样硬化斑块的影响。方法将60例急性脑梗死患者,分为阿托伐他汀单独治疗(对照组)和阿托伐他汀联合普罗布考治疗(观察组),对照组使用阿托伐他汀20mg,每天1次;治疗组在此基础上使用普罗布考0.25g,每天2次,共治疗6个月。分别于治疗前及治疗后6个月测定患者血脂和颈动脉内膜中膜厚度(IMT)。结果两组患者在治疗后6个月较治疗前总胆固醇(TC)、三酰甘油(TG)及低密度脂蛋白胆固醇(LDL-C)明显降低(P<0.01),高密度脂蛋白胆固醇(HDL-C)增高(P<0.05),颈动脉IMT明显降低(P<0.01)。治疗后6个月观察组较对照组TC、LDL-C、TG及颈动脉IMT明显降低(P<0.05),HDL-C增高但差异无统计学意义(P>0.05)。结论普罗布考联合阿托伐他汀治疗急性脑梗死具有协同降脂和降低颈动脉IMT作用,能有效稳定颈动脉粥样硬化斑块。Objective To observe the effect of probucol combined with atorvastatin on the blood lipid and carotid atherosclerosis plaque in the patients with acute cerebral infarction（ACI）. Methods 60 patients with ACI were randomly divided into the control group and the combined treatment group. The control group was given atorvastatin 20 mg, once daily, while on this base the com-bined treatment group was given probucol 0.25 g, twice a day, for 6 months. Blood lipid and carotid intimal medial thickness（IMT） were measured before treatment and in 6 months after treatment. Results Total cholesterol （TC） ,low density lipoprotein （LDL） and triglyceride（TG） after 6-month treatment were significantly decreased than before treatment（P〈0.01）. High density lipopro-tein （HDL） after 6-month treatment was increased markedly in both groups（P〈0.01）. Carotid IMT after 6-months treatment in both groups was declined markedly compared to before treatment. TC,LDL-C,TG and carotid IMT after 6-month treatment in the combined treatment group were declined markedly compared to the control group; HDL-C was increased without statistical differ-ence. Conclusion Probucol combined atorvastatin has the effect of synergically reducing blood lipid and carotid IMT and effectively stabilize carotid atherosclerosis plaque in treating ACI.

关 键 词：普罗布可 阿托伐他汀 脑梗死 动脉粥样硬化 颈动脉 血管中膜 

分 类 号：R743.3[医药卫生—神经病学与精神病学]